"10.1371_journal.pone.0099997","plos one","2014-06-19T00:00:00Z","Iana H Haralambieva; Nathaniel D Lambert; Inna G Ovsyannikova; Richard B Kennedy; Beth R Larrabee; V Shane Pankratz; Gregory A Poland","Mayo Vaccine Research Group, Mayo Clinic, Rochester, Minnesota, United States of America; Division of Biostatistics, Mayo Clinic, Rochester, Minnesota, United States of America; Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, Minnesota, United States of America; Program in Translational Immunovirology and Biodefense, Mayo Clinic, Rochester, Minnesota, United States of America","Conceived and designed the experiments: IH NL IO RK GAP. Performed the experiments: IH NL. Analyzed the data: BL VSP IH. Contributed reagents/materials/analysis tools: IO RK GAP BL VSP. Wrote the paper: IH NL IO RK GAP VSP.","GP is the chair of a Safety Evaluation Committee for novel non-rubella investigational vaccine trials being conducted by Merck Research Laboratories. GP offers consultative advice on vaccine development to Merck & Co. Inc., CSL Biotherapies, Avianax, Sanofi Pasteur, Dynavax, Novartis Vaccines and Therapeutics, PAXVAX Inc, and Emergent Biosolutions. GP and IO hold two patents related to vaccinia peptide research: U.S. Patent “Vaccinia Virus Polypeptides,” U.S. Patent Number: 13/222,862 (issued 31 August 2011), and U.S. Patent “Naturally Processed Measles Virus Peptides from Class II HLA Molecules,” U.S. Patent Number US 2010/0119536 A1 (issued 13 May 2010). These activities have been reviewed by the Mayo Clinic Conflict of Interest Review Board and are conducted in compliance with Mayo Clinic Conflict of Interest policies. This research has been reviewed by the Mayo Clinic Conflict of Interest Review Board and was conducted in compliance with Mayo Clinic Conflict of Interest policies. This does not alter adherence to PLOS ONE policies on sharing data and materials.","2014","06","Iana H Haralambieva","IHH",7,TRUE,5,2,3,6,TRUE,TRUE,FALSE,0,NA,FALSE
